

October 23, 2018



Adial Pharmaceuticals to Present at Dawson James Securities 4th Annual Small Cap Growth Conference

CHARLOTTESVILLE, Va., Oct. 23, 2018 (GLOBE NEWSWIRE) -- **Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW)**, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that William Stilley, President and Chief Executive Officer, will be presenting at the Dawson James Securities 4th Annual Small Cap Growth Conference on Tuesday, October 30th, at 9:00 AM, Eastern Time, at the Wyndham Grand Hotel in Jupiter, Florida.

If you are unable to attend, and would like to view the Company's live webcast, please click the following link (<http://wsw.com/webcast/dawson4/adil/>). The webcast will be archived for one year following the live presentation.

About Dawson James Securities

Dawson James Securities, Inc., a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL. <http://www.dawsonjames.com>.

About Adial Pharmaceuticals, Inc.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of treatments for addictions. The Company's lead investigational new drug candidate, AD04, is a genetically targeted therapeutic agent for the treatment of alcohol use disorder (AUD). A Phase 2b clinical trial of AD04 for the treatment of AUD showed promising results in reducing frequency of drinking, quantity of drinking and heavy drinking (all with statistical significance), and no overt safety concerns (there were no statistically significant serious adverse events reported). The Company plans to commence a Phase 3 clinical trial using AD04 for the potential treatment of AUD in subjects with certain target genotypes, which are to be identified using the Company's proprietary companion diagnostic genetic test. AD04 is also believed to have the potential to treat other addictive disorders such as opioid use disorder, gambling, and obesity.

Contact:

Crescendo Communications, LLC
David Waldman / Natalya Rudman
Tel: 212-671-1021
Email: dwaldman@crescendo-ir.com



Source: Adial Pharmaceutical, Inc.